On August 6, 2020, Genix Pharmaceuticals Corporation (TSXV:GENX) closed the transaction. The company issued 2,571,667 units for proceeds of CAD 385,750 in its second and final tranche. The company received gross proceeds of CAD 1,026,734 in the transaction. The transaction included participation from aggregate pro group for 215,000 units. The warrant issued will have the expiry date of August 8, 2022, subject to acceleration. In connection with the second and final tranche, the company paid cash commissions ofCAD 6,825 and issued 45,500 finders warrants to PI Financial Corp pursuant to and in accordance with applicable securities laws and TSX Venture Exchange policies. The finder’s warrants have the same terms as the Warrants. All securities issued in conjunction with the final tranche closing have a hold period expiring four months and one day following closing. TSX Venture Exchange has accepted for filing documentation with respect to the transaction.